NeuralPress

NeuralPress AI Verified Insights

Vetted by NeuralPress's Multi-Agent Verifier for strict factual validity and event relevance. Our compliance engine cross-checks and filters search results to ensure zero false correlations or misleading content, in full compliance with the Online Safety Act of Sri Lanka.

Primary Sources

jamanetwork.com
Pilot Results for Psilocybin-Assisted Psychotherapy for Cocaine Use ...

Over a 9-year period, Hendricks and colleagues1 piloted psilocybin-assisted therapy for cocaine use disorder (CUD) among 40 adults. Results supported the treatment for improving cocaine-related outcomes (eg, abstinence and relapse) over 180 days posttreatment. Secondary substance use outcomes or...

jamanetwork.com
en.wikipedia.org
Psilocybin - Wikipedia

Psilocybin, also known as 4-phosphoryloxy-N,N-dimethyltryptamine (4-PO-DMT),[a] is a naturally occurring tryptamine alkaloid and investigational drug found in more than 200 species of mushrooms, with hallucinogenic and serotonergic effects.[21][25] Effects include euphoria, changes in perception, a distorted sense of time,[26] and perceived spiritual experiences.PsilocybinINN: PsilocybineSkeletal formula of canonical psilocybinBall-and-stick model of canonical psilocybinClinical dataPronunciation sy-lə-SY-bin, Other namesPsilocybine; Psilocibin; Psylocybin; Psilotsibin; Psilocin phosphate; Psilocin phosphate ester; O-Phosphorylpsilocin; O-Phosphoryl-4-hydroxy-N,N-dimethyltryptamine; 4-Phosphoryloxy-N,N-dimethyltryptamine; 4-PO-DMT; COMP360; COMP-360; CY-39; CY39; PSOP, Psilocybin (USAN US)DependenceliabilityLow[1][2][3][4][5]AddictionliabilityLow[1][6]Routes ofadministration By mouth, intravenous[7] Drug classSerotonergic psychedelic; Hallucinogen; Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist[8]ATC codeNoneLegal statusLegal status AU: S9/S8 (Controlled Drug) BR: Class F2 (Prohibited psychotropics)[9] CA: Schedule III UK: Class A US: Schedule I Pharmacokinetic dataBioavailabilityOral: 52.7 ± 20.4% (as psilocin) (n=3)[10][11][12]Protein binding66%[13]MetabolismLiver, other tissues:[11][10][7][14]• Dephosphorylation (ALPTooltip alkaline phosphatase)• Demethylation and deamination (MAOTooltip monoamine oxidase)• Oxidation (ALDHTooltip aldehyde dehydrogenase)• Glucuronidation (UGTs)Metabolites• Psilocin[11][10][7]• Psilocin-O-glucuronide[10][7]• 4-Hydroxyindole-3-acetaldehyde[10][7]• 4-Hydroxyindole-3-acetic acid (4-HIAA)[10][7]• 4-Hydroxytryptophol[10][7]Onset of actionOral: 0.5–0.8 (range 0.1–1.5) h[15][11]IVTooltip Intravenous injection: immediate[16][17]Elimination half-lifeOral (as psilocin): 2.1–4.7 h (range 1.2–18.6 h)[10][18][19]IVTooltip Intravenous administration (as psilocin): 1.2 h (range 1.8–4.5 h)[10][2]Duration of actionOral: 4–6 h (range 3–12 h)[11][20][21]IVTooltip Intravenous injection: 15–60 min (1–2 mg)[2][12][16][17]ExcretionUrine (mainly as psilocin-O-glucuronide, 2–4% as unchanged psilocin)[10][7][22]Identifiers IUPAC name [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate CAS Number520-52-5 PubChem CID10624DrugBankDB11664ChemSpider10178 UNII2RV7212BP0KEGGD12881 ChEBICHEBI:8614 ChEMBLChEMBL194378 CompTox Dashboard (EPA)DTXSID0048898 ECHA InfoCard100.007.542 Chemical and physical dataFormulaC12H17N2O4PMolar ma...

en.wikipedia.org
bmj.com
Management of obsessive-compulsive disorder in adults - The BMJ

psilocybin for OCD to ... As these trials progress, they may broaden the available toolbox for clinicians managing difficult to treat OCD presentations.

bmj.com
ootwjournal.com
Psilocybin and OCD: Interrupting the Loop | OOTW Journal

They are failed attempts to silence a signal that should switch off but does not. For decades, treatment consisted of SSRIs and cognitive-behavioural therapy, ...

ootwjournal.com